Side-by-side · Research reference
MT-1vsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED9/51 cited
BHuman-MechanisticAUTO-DRAFTED12/36 cited
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
MT-1
Pinealon
Primary target
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
—
Origin
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
MT-1
Pinealon
Standard dose
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
5–10 mg / day for 10 daysKhavinson 2014
Frequency
Every 60 days
Sustained release implant — no daily administration required.
Once daily during cycle
Evidence basis
Phase 3 RCT / FDA-approved orphan drug
Russian clinical trials + in vitroKhavinson 2014
Indication
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
—
Duration
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
10-day cycles, 1–2× per year
Route
Subcutaneous implant — upper arm or abdomen
—
Stability
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
—
Lower / starter dose
—
2.5 mg / day
Reconstitution
—
Bacteriostatic water
Timing
—
No specific time
Half-life
—
Hours
04Side Effects & Safety
Parameter
MT-1
Pinealon
Nausea
Common (>10%) — mild, transient
—
Implant site reaction
Erythema, bruising, tenderness at insertion site
—
Hyperpigmentation
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
—
Melanocytic changes
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
—
Headache
Occasional (MC1R-independent melanocortin effects)
—
Photosensitivity (paradoxical)
Rare phototoxic reactions despite melanin increase
—
Contamination risk (unregulated)
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
—
Injection site reaction
—
Mild irritation
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
MT-1
Pinealon
1. Implant insertion
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Site care
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
SQ — abdomen preferred.
3. Release kinetics
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
Daily during cycle, any time.
4. Repeat dosing
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Monitoring
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
MT-1
— no documented stacks
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation